63323-712 NDC - KABIVEN (DEXTROSE, SOYBEAN OIL, ELECTROLYTES, LYSINE, PHENYLALANINE, LEUCINE, VALINE, THREONINE, METHIONINE, ISOLEUCINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, HISTIDINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID AND TYROSINE)

Drug Information

Product NDC: 63323-712

Proprietary Name: Kabiven

Non Proprietary Name: Dextrose, Soybean oil, Electrolytes, Lysine, Phenylalanine, Leucine, Valine, Threonine, Methionine, Isoleucine, Tryptophan, Alanine, Arginine, Glycine, Proline, Histidine, Glutamic Acid, Serine, Aspartic Acid and Tyrosine

Active Ingredient(s):
  • 467 mg/100mL ALANINE;
  • 330 mg/100mL ARGININE;
  • 99 mg/100mL ASPARTIC ACID;
  • 29 mg/100mL CALCIUM CHLORIDE;
  • 9.8 g/100mL DEXTROSE MONOHYDRATE;
  • 164 mg/100mL GLUTAMIC ACID;
  • 231 mg/100mL GLYCINE;
  • 199 mg/100mL HISTIDINE;
  • 164 mg/100mL ISOLEUCINE;
  • 231 mg/100mL LEUCINE;
  • 263 mg/100mL LYSINE HYDROCHLORIDE;
  • 96 mg/100mL MAGNESIUM SULFATE HEPTAHYDRATE;
  • 164 mg/100mL METHIONINE;
  • 231 mg/100mL PHENYLALANINE;
  • 174 mg/100mL POTASSIUM CHLORIDE;
  • 199 mg/100mL PROLINE;
  • 131 mg/100mL SERINE;
  • 239 mg/100mL SODIUM ACETATE;
  • 147 mg/100mL SODIUM GLYCEROPHOSPHATE ANHYDROUS;
  • 3.9 g/100mL SOYBEAN OIL;
  • 164 mg/100mL THREONINE;
  • 55 mg/100mL TRYPTOPHAN;
  • 6.7 mg/100mL TYROSINE;
  • 213 mg/100mL VALINE


Administration Route(s): INTRAVENOUS

Dosage Form(s): INJECTION, EMULSION

Pharmacy Class(es):
  • Amino Acid [EPC];
  • Amino Acids [CS];
  • Blood Coagulation Factor [EPC];
  • Calcium [CS];
  • Calculi Dissolution Agent [EPC];
  • Cations;
  • Divalent [CS];
  • Increased Coagulation Factor Activity [PE];
  • Increased Large Intestinal Motility [PE];
  • Increased Large Intestinal Motility [PE];
  • Increased Large Intestinal Motility [PE];
  • Increased Large Intestinal Motility [PE];
  • Inhibition Large Intestine Fluid/Electrolyte Absorption [PE];
  • Inhibition Large Intestine Fluid/Electrolyte Absorption [PE];
  • Inhibition Large Intestine Fluid/Electrolyte Absorption [PE];
  • Inhibition Large Intestine Fluid/Electrolyte Absorption [PE];
  • Inhibition Small Intestine Fluid/Electrolyte Absorption [PE];
  • Lipid Emulsion [EPC];
  • Lipids [CS];
  • Magnesium Ion Exchange Activity [MoA];
  • Osmotic Activity [MoA];
  • Osmotic Activity [MoA];
  • Osmotic Activity [MoA];
  • Osmotic Activity [MoA];
  • Osmotic Laxative [EPC];
  • Osmotic Laxative [EPC];
  • Osmotic Laxative [EPC];
  • Osmotic Laxative [EPC];
  • Potassium Compounds [CS];
  • Potassium Salt [EPC];
  • Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]

Labeler Information

Labeler Name: Fresenius Kabi USA, LLC
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: NDA200656
Marketing Category: NDA
Start Marketing Date:8/25/2014

Package Information

No. Package Code Package Description Billing Unit
163323-712-101026 mL in 1 BAG (63323-712-10)ML
263323-712-151540 mL in 1 BAG (63323-712-15)ML
363323-712-202053 mL in 1 BAG (63323-712-20)ML
463323-712-252566 mL in 1 BAG (63323-712-25)ML

NDC Record

Field Name Field Value Definition
PRODUCT NDC63323-712The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEKabivenThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEDextrose, Soybean oil, Electrolytes, Lysine, Phenylalanine, Leucine, Valine, Threonine, Methionine, Isoleucine, Tryptophan, Alanine, Arginine, Glycine, Proline, Histidine, Glutamic Acid, Serine, Aspartic Acid and TyrosineThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMEINJECTION, EMULSIONThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEINTRAVENOUSThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE8/25/2014This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMENDAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERNDA200656This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEFresenius Kabi USA, LLCName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEALANINE; ARGININE; ASPARTIC ACID; CALCIUM CHLORIDE; DEXTROSE MONOHYDRATE; GLUTAMIC ACID; GLYCINE; HISTIDINE; ISOLEUCINE; LEUCINE; LYSINE HYDROCHLORIDE; MAGNESIUM SULFATE HEPTAHYDRATE; METHIONINE; PHENYLALANINE; POTASSIUM CHLORIDE; PROLINE; SERINE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE ANHYDROUS; SOYBEAN OIL; THREONINE; TRYPTOPHAN; TYROSINE; VALINEAn active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH467; 330; 99; 29; 9.8; 164; 231; 199; 164; 231; 263; 96; 164; 231; 174; 199; 131; 239; 147; 3.9; 164; 55; 6.7; 213 
ACTIVE INGRED UNITmg/100mL; mg/100mL; mg/100mL; mg/100mL; g/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL; g/100mL; mg/100mL; mg/100mL; mg/100mL; mg/100mL 
PHARM CLASSESAmino Acid [EPC], Amino Acids [CS], Blood Coagulation Factor [EPC], Calcium [CS], Calculi Dissolution Agent [EPC], Cations, Divalent [CS], Increased Coagulation Factor Activity [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Small Intestine Fluid/Electrolyte Absorption [PE], Lipid Emulsion [EPC], Lipids [CS], Magnesium Ion Exchange Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Potassium Compounds [CS], Potassium Salt [EPC], Stimulation Large Intestine Fluid/Electrolyte Secretion [PE] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 2/1/2023